GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

XBIO · Mar 31, 2026

Xenetic Biosciences, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001683168-26-003727General Corporate
Operating cash generation90thOwn-history percentile · N=20
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-66.47% · OPTIONAL · VALID

Revenue growth47thOwn-history percentile · N=17
Evidence method

Yoy · gp.fundamentals.revenue

36.01% · CORE · VALID

Operating margin95thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.operating_margin

-62.23% · CORE · VALID

R&D intensity10thOwn-history percentile · N=20
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

81.97% · OPTIONAL · VALID

SBC intensity0thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

1.40% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History19 statesSelf-history eligible
Dec 31, 20210/5 normalizedLevel 3Mar 31, 20220/5 normalizedLevel 3Jun 30, 20220/5 normalizedLevel 3Sep 30, 20220/5 normalizedLevel 3Dec 31, 20224/5 normalizedLevel 3Mar 31, 20234/5 normalizedLevel 3Jun 30, 20234/5 normalizedLevel 3Sep 30, 20234/5 normalizedLevel 3Dec 31, 20235/5 normalizedLevel 3Mar 31, 20245/5 normalizedLevel 3Jun 30, 20245/5 normalizedLevel 3Sep 30, 20245/5 normalizedLevel 3Dec 31, 20245/5 normalizedLevel 3Mar 31, 20255/5 normalizedLevel 3Jun 30, 20255/5 normalizedLevel 3Sep 30, 20255/5 normalizedLevel 3Dec 31, 20255/5 normalizedLevel 3Mar 31, 20265/5 normalizedLevel 3Jun 30, 20265/5 normalizedLevel 4
Period transition

What moved in the state?

Cash Generation Increased
Previous
-76.83%
Current
-66.47%
Delta
10.35%
Growth Increased
Previous
19.04%
Current
36.01%
Delta
16.97%
Profitability Increased
Previous
-95.23%
Current
-62.23%
Delta
33.01%
R And D Intensity Decreased
Previous
102.99%
Current
81.97%
Delta
-21.02%
Sbc Intensity Decreased
Previous
2.18%
Current
1.40%
Delta
-0.77%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Transitioned To · XBIO CASH_GENERATION_INCREASED →Transitioned To · XBIO GROWTH_INCREASED →Transitioned To · XBIO PROFITABILITY_INCREASED →Transitioned To · XBIO R_AND_D_INTENSITY_DECREASED →Transitioned To · XBIO SBC_INTENSITY_DECREASED →Transitioned To · XBIO Fundamental State →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.